1-(3,4-dichlorophenyl)tetrazole | 337935-56-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(3,4-dichlorophenyl)tetrazole
• CAS: 337935-56-5
• 化学式: C₇H₄Cl₂N₄
• 分子量: 215.042
• InChiKey: ZUFRXMARKSYERT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-碘噻吩 、 1-(3,4-dichlorophenyl)tetrazole 在 copper(l) iodide 、 三(2-呋喃基)膦 、 palladium diacetate 、 caesium carbonate 作用下， 以 乙腈 为溶剂， 反应 5.0h， 以57%的产率得到1-(3,4-dichlorophenyl)-5-(thiophen-2-yl)-1H-tetrazole
  参考文献：
  名称：

  Direct C−H Arylation and Alkenylation of 1-Substituted Tetrazoles: Phosphine As Stabilizing Factor

  摘要：

  Direct arylation and alkenylation of 1-substituted tetrazoles was achieved via Pd catalysis in the presence of CuI and CS2CO3. Unlike the related reactions of imidazoles and purines, phosphine ligand was necessary to prevent the intermediate tetrazolyl-Pd-II species from fragmentation into the corresponding cyanamide, Various 1,5-disubstituted tetrazoles were prepared with good to excellent isolated yields.

  DOI：

  10.1021/jo902180u

文献信息

• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：UCL BUSINESS LTD

  公开号：WO2020043866A1

  公开（公告）日：2020-03-05

  A compound for use in the treatment of a disease ameliorated by the inhibition of Notum of formula (I): (I)

  一种用于治疗通过抑制公式（I）中的Notum改善的疾病的化合物：（I）
• Synthesis of 6-tetrazolyl-substituted sulfocoumarins acting as highly potent and selective inhibitors of the tumor-associated carbonic anhydrase isoforms IX and XII
  作者：Aiga Grandane、Muhammet Tanc、Raivis Zalubovskis、Claudiu T. Supuran

  DOI：10.1016/j.bmc.2014.01.043

  日期：2014.3

  A series of 6-substituted sulfocoumarins incorporating substituted-1,2,3,4-tetrazol-5-yl moieties were synthesized by reaction of 6-iodo-sulfocoumarin and the corresponding tetrazole via the CH activation reaction. The new sulfocoumarins incorporating alkyl and substituted aryl moieties at the 1-position of the tetrazole, were investigated for the inhibition of four human (h) carbonic anhydrase (hCA, EC 4.2.1.1) isoforms, the cytosolic hCA I and II; and the transmembrane, tumor-associated hCA IX and XII. The tetrazole-substituted sulfocoumarins did not inhibit the ubiquitous, off-target cytosolic isoforms (K(I)s > 10 mu M) but showed effective inhibition against the two transmembrane CAs, with KIs ranging from 6.5 to 68.6 nM against hCA IX, and between 4.3 and 59.8 nM against hCA XII. As hCA IX and XII are validated anti-tumor targets, such prodrug, isoform-selective inhibitors as the sulfocoumarins reported here, may be useful for identifying suitable drug candidates for clinical trials. (C) 2014 Elsevier Ltd. All rights reserved.
• COMPOUNDS
  申请人：UCL Business Ltd

  公开号：EP3843844A1

  公开（公告）日：2021-07-07